<DOC>
	<DOCNO>NCT03093480</DOCNO>
	<brief_summary>The primary purpose study describe time tolerization rFVIIIFc participant within maximum 12 month ITI treatment .</brief_summary>
	<brief_title>A Study Evaluate Efficacy rFVIIIFc Immune Tolerance Induction ( ITI ) Severe Hemophilia A Participants With Inhibitors Undergoing First ITI Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Ability participant legally authorize representative ( e.g. , parent legal guardian ) understand purpose risk study provide sign date informed consent authorization use protect health information accordance national local participant privacy regulation Male participant age diagnose severe hemophilia A ( confirm medical record ) Diagnosed high titer inhibitor ( historical peak great equal ( &gt; = ) 5 Bethesda unit per milliliter ( BU/mL ) , accord medical record ) Previously treat plasmaderived recombinant conventional Extended HalfLife FVIII Other coagulation disorder ( ) addition hemophilia A Previous immune tolerance induction ( ITI ) History hypersensitivity anaphylaxis associate recombinant coagulation factor VIII Fc ( rFVIIIFc ) administration Planned major surgery defer study completion ( minor surgery tooth extraction insertionreplacement central venous access device allow ) Abnormal renal function ( serum creatinine great [ &gt; ] 2.0 milligram per deciliter [ mg/dL ] ) assess local laboratory Serum alanine aminotransferase aspartate aminotransferase &gt; 5 Ã— upper limit normal ( ULN ) assess local laboratory</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>